Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

Objectives. To demonstrate the pharmacokinetic equivalence of CT-P13 and its innovator infliximab (IFX) in Japanese patients with rheumatoid arthritis (RA), and to compare the efficacy and safety of these drugs, administered for 54 weeks. Methods. In a randomized, double-blind, parallel-group, multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Yamanaka, Hisashi, Tanaka, Yoshiya, Sakurai, Takeo, Saito, Kazuyoshi, Ohtsubo, Hideo, Lee, Sang Joon, Nambu, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732515/
https://www.ncbi.nlm.nih.gov/pubmed/25736355
http://dx.doi.org/10.3109/14397595.2015.1022297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732515/
https://www.ncbi.nlm.nih.gov/pubmed/25736355
http://dx.doi.org/10.3109/14397595.2015.1022297

Ejemplares similares